Assessing the clinical benefit of systemic anti-cancer treatments in the Netherlands:The impact of different thresholds for effectiveness
BACKGROUND: In the Netherlands, the clinical benefit of systemic anti-cancer treatments (SACTs) is assessed by the Committee for the Evaluation of Oncological Agents (cieBOM). For non-curative SACTs, the assessment is based on the hazard ratio (HR) for progression-free survival and/or overall survival (OS), and the difference in median survival. We evaluated the impact of different thresholds for effectiveness by reassessing the clinical benefit of SACTs. METHODS: We reassessed SACTs that were initially assessed by cieBOM between 2015 and 2017. Four scenarios were formulated: replacing an "OR"... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2024 |
Reihe/Periodikum: | Leeneman , B , Xander , N S H , Fiets , W E , de Jong , W K , Uyl , N E M , Wymenga , A N M , Reyners , A K L & Uyl-de Groot , C A 2024 , ' Assessing the clinical benefit of systemic anti-cancer treatments in the Netherlands : The impact of different thresholds for effectiveness ' , European Journal of Cancer , vol. 202 , 114002 . https://doi.org/10.1016/j.ejca.2024.114002 |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-27602155 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://hdl.handle.net/11370/d5c16150-2585-4692-a988-91cd841e7205 |